Chardan raised the firm’s price target on Avidity Biosciences to $33 from $23 and keeps a Buy rating on the shares. The company’s newly announced efficacy and safety data from the MARINA-OLE study in adults with myotonic dystrophy type 1 “adds to and is concordant with the prior data”, allowing the company to advance into an informed registration study with greater confidence,the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RNA:
- Avidity Biosciences Reveals Promising Trial Results and Phase 3 Plans
- Avidity Biosciences Launches Major Stock and Warrants Placement
- Avidity Biosciences sells 15.22M shares at $16.50 in private placement
- 3 Best Stocks to Buy Now, 2/29/2024, According to Top Analysts
- Avidity Biosciences files to sell 5.075M shares of common stock for holders
